betaxolol has been researched along with Angor Pectoris in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and twelve beta-blockers-naive outpatients with stable angina pectoris were randomized to receive betaxolol, 20 mg once daily or metoprolol tartrate, 50 mg twice daily for 8 weeks." | 9.12 | Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. ( Kardas, P, 2007) |
| "Betaxolol, a long-acting cardioselective beta-blocker, was tested alone and in combination with long-acting nitrates in a multicenter, double-blind, parallel, placebo-controlled study of 3 weeks duration in patients with stable angina pectoris." | 9.07 | Betaxolol in the treatment of stable angina pectoris. ( Bittar, N; Chrysant, SG, 1994) |
| "Compared with placebo, adding betaxolol 20 mg every day to nifedipine (up to 60 mg/day in divided doses) or diltiazem (up to 360 mg/day in divided doses) for a 3-week treatment period in 135 patients with stable angina pectoris significantly (p < 0." | 9.07 | Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. ( Friedman, R; Glasser, SP; Smith, LK; Talibi, T; Weir, EK, 1994) |
| "We examined the importance of a long plasma half-life (t1/2) on the antianginal effects of beta-blockade by comparing equivalent doses of once-daily atenolol 100 mg (t1/2 6-8 h) and betaxolol 20 mg (t1/2 20-22 h) in a double-blind placebo-controlled cross-over study of 20 patients with stable angina pectoris." | 9.07 | Twenty-four-hour beta-blockade in stable angina pectoris: a study of atenolol and betaxolol. ( Dargie, HJ; Findlay, IN; McLenachan, JM; Wilson, JT, 1992) |
| "To assess the efficacy of oral betaxolol in the treatment of stable exertional angina pectoris and to determine the relationship between betaxolol doses/serum concentrations and clinical/hemodynamic responses the authors studied 24 patients prior to and following stepwise administration of 5, 10, 20, 40, and 80 mg doses." | 9.06 | Efficacy of betaxolol in the treatment of stable exertional angina pectoris: a dose-ranging study. ( Alpert, MA; Beach, CL; Flaker, GC; Morgan, RJ; Mukerji, V; Sanfelippo, JF; Singh, A; Villarreal, D, 1990) |
| "To assess the effect of beta blockade on left ventricular (LV) performance in patients with LV dysfunction and stable angina pectoris, 18 subjects taking a placebo followed by incremental doses of the cardioselective beta-adrenergic blocking agent betaxolol (5, 10, 20, 40 and 80 mg/day) were studied." | 9.06 | Effect of beta blockade with betaxolol on left ventricular systolic function in chronic stable angina pectoris and left ventricular dysfunction. ( Alpert, MA; Flaker, GC; Holmes, RA; Morgan, RJ; Mukerji, V; Sanfelippo, JF; Singh, A; Villarreal, D, 1986) |
| "The effect of three different oral doses, 5 mg, 10 mg and 20 mg of betaxolol (BTX), a new long acting cardioselective beta-adrenergic blocking drug, on exercise tolerance was studied in a randomized double blind, cross-over study with latin square distribution in nine male patients with angina pectoris, under continuous therapy with oral nitroglycerin." | 9.05 | Dose related efficacy of betaxolol in combination with nitroglycerin in patients with angina pectoris: a double blind cross-over study. ( Kesteloot, H; Stroobandt, R, 1984) |
| "Betaxolol is a new, highly cardioselective, once-a-day beta blocker with a long half-life (mean 16 hours)." | 6.67 | Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group. ( Narahara, KA, 1990) |
| "One hundred and twelve beta-blockers-naive outpatients with stable angina pectoris were randomized to receive betaxolol, 20 mg once daily or metoprolol tartrate, 50 mg twice daily for 8 weeks." | 5.12 | Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. ( Kardas, P, 2007) |
| "Betaxolol, a long-acting cardioselective beta-blocker, was tested alone and in combination with long-acting nitrates in a multicenter, double-blind, parallel, placebo-controlled study of 3 weeks duration in patients with stable angina pectoris." | 5.07 | Betaxolol in the treatment of stable angina pectoris. ( Bittar, N; Chrysant, SG, 1994) |
| "Compared with placebo, adding betaxolol 20 mg every day to nifedipine (up to 60 mg/day in divided doses) or diltiazem (up to 360 mg/day in divided doses) for a 3-week treatment period in 135 patients with stable angina pectoris significantly (p < 0." | 5.07 | Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. ( Friedman, R; Glasser, SP; Smith, LK; Talibi, T; Weir, EK, 1994) |
| "We examined the importance of a long plasma half-life (t1/2) on the antianginal effects of beta-blockade by comparing equivalent doses of once-daily atenolol 100 mg (t1/2 6-8 h) and betaxolol 20 mg (t1/2 20-22 h) in a double-blind placebo-controlled cross-over study of 20 patients with stable angina pectoris." | 5.07 | Twenty-four-hour beta-blockade in stable angina pectoris: a study of atenolol and betaxolol. ( Dargie, HJ; Findlay, IN; McLenachan, JM; Wilson, JT, 1992) |
| "To assess the efficacy of oral betaxolol in the treatment of stable exertional angina pectoris and to determine the relationship between betaxolol doses/serum concentrations and clinical/hemodynamic responses the authors studied 24 patients prior to and following stepwise administration of 5, 10, 20, 40, and 80 mg doses." | 5.06 | Efficacy of betaxolol in the treatment of stable exertional angina pectoris: a dose-ranging study. ( Alpert, MA; Beach, CL; Flaker, GC; Morgan, RJ; Mukerji, V; Sanfelippo, JF; Singh, A; Villarreal, D, 1990) |
| "To assess the effect of beta blockade on left ventricular (LV) performance in patients with LV dysfunction and stable angina pectoris, 18 subjects taking a placebo followed by incremental doses of the cardioselective beta-adrenergic blocking agent betaxolol (5, 10, 20, 40 and 80 mg/day) were studied." | 5.06 | Effect of beta blockade with betaxolol on left ventricular systolic function in chronic stable angina pectoris and left ventricular dysfunction. ( Alpert, MA; Flaker, GC; Holmes, RA; Morgan, RJ; Mukerji, V; Sanfelippo, JF; Singh, A; Villarreal, D, 1986) |
| "The effect of three different oral doses, 5 mg, 10 mg and 20 mg of betaxolol (BTX), a new long acting cardioselective beta-adrenergic blocking drug, on exercise tolerance was studied in a randomized double blind, cross-over study with latin square distribution in nine male patients with angina pectoris, under continuous therapy with oral nitroglycerin." | 5.05 | Dose related efficacy of betaxolol in combination with nitroglycerin in patients with angina pectoris: a double blind cross-over study. ( Kesteloot, H; Stroobandt, R, 1984) |
| "This study examined the effects of beta blockade with betaxolol, a cardioselective, lipid-soluble, beta-adrenergic-blocking agent, on rest and exercise systolic and diastolic left ventricular function in 15 patients, aged 40 to 70 years (mean = 52), with chronic stable angina pectoris." | 3.67 | Effects of beta blockade on systolic and diastolic left ventricular function at rest and during exercise in patients with chronic stable angina pectoris. ( Fernandes, M; Fiorentini, R; Hakki, AH; Heo, J; Iskandrian, AS; Nestico, PF; Schenk, C, 1987) |
| "Betaxolol is a new, highly cardioselective, once-a-day beta blocker with a long half-life (mean 16 hours)." | 2.67 | Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group. ( Narahara, KA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dupliakov, DV | 1 |
| Glukhova, VL | 1 |
| Vozhdaeva, ZI | 1 |
| Golovina, GA | 1 |
| Kardas, P | 1 |
| Stroobandt, R | 1 |
| Kesteloot, H | 1 |
| Chrysant, SG | 1 |
| Bittar, N | 1 |
| Glasser, SP | 1 |
| Friedman, R | 1 |
| Talibi, T | 1 |
| Smith, LK | 1 |
| Weir, EK | 1 |
| Burger, AJ | 1 |
| Kamalesh, M | 1 |
| Kumar, S | 1 |
| Nesto, R | 1 |
| McLenachan, JM | 1 |
| Findlay, IN | 1 |
| Wilson, JT | 1 |
| Dargie, HJ | 1 |
| Alpert, MA | 3 |
| Mukerji, V | 3 |
| Villarreal, D | 3 |
| Singh, A | 3 |
| Flaker, GC | 2 |
| Sanfelippo, JF | 3 |
| Beach, CL | 1 |
| Morgan, RJ | 3 |
| Narahara, KA | 1 |
| Brügmann, U | 1 |
| Blasini, R | 1 |
| Holmes, RA | 2 |
| Sunderrajan, EV | 1 |
| Iskandrian, AS | 1 |
| Nestico, PF | 1 |
| Hakki, AH | 1 |
| Heo, J | 1 |
| Fernandes, M | 1 |
| Fiorentini, R | 1 |
| Schenk, C | 1 |
12 trials available for betaxolol and Angor Pectoris
| Article | Year |
|---|---|
[Cardioselective beta-adrenoblockers in patients with stable angina pectoris. Comparison of efficacy and safety].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Benzopyrans; Betaxolol; Bisoprolol; Blood Flow Velocit | 2006 |
Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Betaxolol; Dose-Response Relationship, Dr | 2007 |
Dose related efficacy of betaxolol in combination with nitroglycerin in patients with angina pectoris: a double blind cross-over study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Betaxolol; Clinical Trials as Topic; Doub | 1984 |
Betaxolol in the treatment of stable angina pectoris.
Topics: Angina Pectoris; Betaxolol; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; | 1994 |
Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Betaxolol; Chronic Disease; Diltiazem; Double-Blind | 1994 |
Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Autonomic Nervous System; Betaxolol; Electro | 1996 |
Twenty-four-hour beta-blockade in stable angina pectoris: a study of atenolol and betaxolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Angina Pectoris; Atenolol; Betaxolol; Blood | 1992 |
Efficacy of betaxolol in the treatment of stable exertional angina pectoris: a dose-ranging study.
Topics: Angina Pectoris; Betaxolol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Exercise Tes | 1990 |
Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group.
Topics: Angina Pectoris; Betaxolol; Double-Blind Method; Drug Administration Schedule; Electrocardiography, | 1990 |
[Comparison of the effect of a selective and a nonselective beta receptor blocker on the ischemic ST segment, lung function and stress-induced decrease in blood glucose].
Topics: Adrenergic beta-Antagonists; Airway Resistance; Angina Pectoris; Betaxolol; Blood Glucose; Blood Pre | 1986 |
Effect of beta blockade with betaxolol on left ventricular systolic function in chronic stable angina pectoris and left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Betaxolol; Clinical Trials as Topic; Heart Function Te | 1986 |
Effect of beta-blockade on right ventricular performance in patients with and without right ventricular dysfunction due to coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Betaxolol; Exercise Test; Heart Ventricles; Hemodynami | 1986 |
1 other study available for betaxolol and Angor Pectoris
| Article | Year |
|---|---|
Effects of beta blockade on systolic and diastolic left ventricular function at rest and during exercise in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Betaxolol; Chronic Disease; Female; Human | 1987 |